FREMONT, Calif. and MELBOURNE, Australia, Feb. 17, 2012
/PRNewswire-Asia/ -- Velos, Inc., the trusted leader in clinical
research management software, is pleased to announce its largest
international multi-site deployment of Velos eResearch through a
partnership with Cancer Trials Australia (CTA). Currently, eight
sites are operating on the Velos platform, and the results thus far
have been extremely positive. These sites include the Peter
MacCallum Cancer Centre, Austin Health, and the Royal Melbourne
Hospital.
"It has met our expectations in what we see as a complex logistics
environment," said Marcus Clark, CEO of CTA. By the end of first
quarter 2012, fourteen oncology clinical trial centers in the
states of Victoria and New South Wales are scheduled to use Velos
eResearch to provide integrated administrative management of their
trial portfolios.
CTA is a non-profit, member-driven organization that works on
behalf of both public and private hospitals to perform research
governance, administration, and financial services, allowing the
staff at these oncology trial centers to focus on patient care. In
2009, CTA and six of its members investigated a more efficient way
to track and manage research information. CTA sites had been
operating on a variety of decentralized processes that stifled the
flow of timely information, which resulted in insufficient data
analysis and impinged on resource priorities. CTA examined a number
of different software products and encouraged users, such as
research nurse managers, to engage in the selection of the product
that would work best for them. "CTA members wanted a thoroughly
proven product," recalled Mr. Clark.
CTA engaged Velos and both organizations worked with the research
nurses to evaluate the product. "We believed that Velos eResearch's
adaptability, as well as its advanced research administration and
financial capabilities, would provide CTA and its sites with the
perfect solution," explained Kamar Aulakh, Velos Chief Operating
Officer. "Velos is excited to bring its innovative technology and
clinical research expertise to Australia, and it looks forward to a
successful partnership with CTA."
After examining a number of different systems, CTA selected Velos
eResearch. "As the application has been implemented across CTA
sites, the results have been meeting our milestones, especially
with the collection of patient visit data and streamlining of
financial data flow. We are able to leverage the Velos eResearch
platform to provide consolidated information across our sites,
including visit monitoring, financial tracking, sponsor billing,
budgeting, and customized reporting. CTA initiates over forty
commercial studies at multiple sites every year, so it's important
to invoice accurately and promptly. With Velos eResearch, we can
achieve this position consistently, preventing build-up of data for
invoicing," commented Mr. Clark.
About Cancer Trials Australia:
CTA is a Melbourne-based not-for-profit service organization that
conducts cancer clinical trials on behalf of investigators and
sponsors, namely biotechnology and pharmaceutical companies. As a
member-based organization comprised of sixteen research institutes
and hospitals, CTA has access to a diverse range of expertise and
technology.
About Velos:
Velos is the trusted clinical trial management resource for
investigators, sponsors, and academic leaders throughout the world.
Velos eResearch is deployed for clinical research in all parts of
the healthcare enterprise and supports a broad diversity of
clinical departments and functional needs. Velos integrates the
clinical, administrative, and financial information needs of
research management, with an emphasis on flexibility, workflow, and
empowering clinical innovation. Founded in 1996, Velos, Inc. is
privately held with headquarters in Fremont, California.
*This press release may contain forward-looking statements that are
subject to risks and uncertainties that could cause actual results
to differ materially from those set forth in the forward-looking
statements.
SOURCE﹛Velos, Inc.